We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Virbac : Declaration of the number of shares and voting rights 12/2025 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20258 390 660Gross total of voting rights : 12 704 596Net total* of voting rights : 12 69...
Virbac : Déclaration d'actions et de droits de vote 12/2025 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote31 Décembre 20258 390 660Total brut de droits de vote : 12 704 596Total net* de droits de vote : 12 691 760 Total net* = nombre total de droits de vote attachés au...
RUBIS: Half-year statement on Rubis’ liquidity agreement with Exane BNP Paribas Paris, 8 January, 2026 – 5:45 pm Pursuant to the liquidity agreement that Rubis has entered into with Exane BNP Paribas, the liquidity account presented the following balances as at the settlement date of 31 December 2025: 30,965 Rubis shares€1,910,024 The following trades were made in the second half of 2025: 166,030 securities were purchased for a total of €5,030,275 (1,243 transactions)194,785 securities were sold for a total of €5,922,337 (1,457 transactions) Reminder: The previous half-year statemen...
RUBIS: Bilan semestriel du contrat de liquidité de Rubis contracté avec la société Exane BNP Paribas Paris, le 8 janvier 2026, 17h45 Au titre du contrat de liquidité confié par la société Rubis à Exane BNP Paribas, en date de dénouement du 31 décembre 2025, les moyens suivants figuraient au compte de liquidité : 30 965 titres Rubis1 910 024 € Au cours du 2ème semestre 2025, il a été négocié un total de : À l'achat, 166 030 titres, pour un montant de 5 030 275 € (1 243 transactions)À la vente, 194 785 titres, pour un montant de 5 922 337 € (1 457 transactions) Il est rappelé que : ...
RUBIS: Information relating to the total number of voting rights and shares as of 31/12/2025 Paris, 6 January 2026, 5:45 pm INFORMATION ON TOTAL NUMBER OF VOTING RIGHTS AND NUMBER OF SHARES PURSUANT TO ARTICLE L.233-8 II OF THE FRENCH COMMERCIAL CODE AND ARTICLE 223-16 OF THE GENERAL REGULATION OF THE FRENCH FINANCIAL MARKETS AUTHORITY DateClass of sharesNumber of sharesNumber of theoretical voting rightsNumber of exercisable voting rights (excluding shares bought back by the Company (deprived of voting rights) and shares deprived of voting rights in accordance with art. L. 233-14 of t...
RUBIS: Déclaration de capital et de droits de vote au 31/12/2025 Paris, le 6 janvier 2026, 17h45 INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS PRÉVUES PAR L’ARTICLE L. 233-8 II DU CODE DE COMMERCE ET L’ARTICLE 223-16 DU RÈGLEMENT GÉNÉRAL DE L’AUTORITÉ DES MARCHÉS FINANCIERS DateCatégorie d’actionsNombre d’actionsNombre de droits de vote théoriquesNombre de droits de vote exerçables(hors actions autodétenues (privées du droit de vote) et actions privées du droit de vote conformément à l’article L. 233-14 du Code de commerce)31 décembre 2025Actions ordinaires (1,25 € ...
VIRBAC: Feline Hyperthyroidism: Virbac acquires Thyronorm Acquisition provides Virbac with a leading specialty product, in a growing segment, to improve the quality of life for senior cats.We are delighted to announce the acquisition of an innovative drug from Norbrook to stabilize feline hyperthyroidism. Virbac will ensure the direct distribution of this treatment under the Thyronorm brand in the United Kingdom, Australia, and New Zealand, and under the Felanorm brand in the United States. In Europe, distribution will continue to be managed by Boehringer Ingelheim and Elanco (in Germany) b...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.